ENCINO, Calif., Feb. 25, 2013 /PRNewswire/ -- Secretropin®, the first clinically proven, 100% natural stimulator of growth hormone has gained the trust of the medical community since 2001. Although classified as a natural food supplement, Secretropin® is only available through physicians due to its clinically proven ability to increase the body's own production and release of growth hormone.
Developed in 2001, Secretropin® received early medical recognition for 2 key reasons: one, its reproducible effectiveness; and two, its preferred oral delivery route as opposed to injections of growth hormone. In as little as 4 weeks, Secretropin® has been shown to increase the production of growth hormone by 50 – 650% while being delivered as an oral spray. Secretropin's oral delivery system (ODS) owes its effectiveness to the latest nanoliposomal technology, which wraps the active agents in a protective envelop. Until this delivery technology was available, stomach acid would inactivate and destroy the active agents responsible for the stimulated increase in growth hormone.
Prior to Secretropin®, injectable growth hormone was the only other viable option for treating Adult GH Deficiency. Fortunately, the nanoliposomal technology protects the complex, allowing for optimal absorption and leading to a more natural increase in growth hormone levels - thus eliminating the less desirable approach of daily injections.
On the financial side, the present global market for injectable human growth hormone (HGH) therapy is estimated to exceed $3B. The market is growing at a projected 15 to 20% rate as the world medical community recognizes the benefits to maintaining healthy hormone levels throughout life. Currently, injectable GH therapy can cost over $800/month, and with the technological advances captured by Secretropin®, the cost range has been significantly reduced to between $150 and $200/month.
The Millennium Health Center, Inc. participated in the development of Secretropin® and provides ongoing clinical research (report). As of January 2011, there are over 10,000 patient months of data being compiled by a number of independent centers throughout the U.S., Australia, New Zealand, Russia, Thailand, Indonesia, China, and Dubai. So far, Secretropin's ability to increase growth hormone production has been reported in excess of 90% of the cases.
For additional information:
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE Millennium Health Centers, Inc.